Dear Investor friends, Today I am expressing my opinion on Chemical company.
SAMRAT PHARMACHEM LTD (530125)
Samrat Pharmachem Limited is an ISO 9000 Gujrat based company
incorporated in1992.Its promoter is having vast experience in Pharmachem business.
The Company is currently manufacturing Iodine salts & Bromine salts. The
finished products produced by the Company are used in various industries like
Pharmaceuticals, Chemicals, Food, Fertilizer, Salt etc.
Company became public in 1995, immediately after company has acquired
more land adjacent to the original factory premises to cater the production
demand. In 2006 Company has expanded its business by constructing the new
manufacturing facility and in 2011 company has made its corporate office in
Mumbai.
PRODUCTS
The company has state of the art
plant at Ankleshwar. The products of the Company are well received in Indian
& Foreign markets. As mentioned earlier company produces products of Iodine
derivatives which is having a huge demand in Pharma and Chemical sector.The Company's products include Calcium iodate monohydrate, Copper
iodide, Hydriodic acid 47%, Iodine, Iodine monochloride, Iodoethane (Ethyl
iodide), Potassium bromide, Potassium iodate, Potassium iodide, Potassium
metaperiodate, Sodium iodide, Sodium iodate, Sodium metaperiodate, Hydriodic
acid 57% and Trimethyl sulfoxoniumiodide.
Following are the main products of the company.
Its plant and machinery includes centrifuges, tray driers, stirrers,
vacuum pumps, chilling plant, shifter, electrolytic cells, electric lift,
sewing machine, filtration unit, rectifiers, electrolytic cells and boilers.
Company is having its own Effluent treatment plant for the effluent
treatment generated from the plant. It is having modern facilities to cater the
stringent pollution norms.
PLEASE NOTE: THIS IS NOT A RESEARCH REPORT AND NOT ANY RECOMMENDATION REPORT.
Company website: Click here
FINANCIALS AND OUTLOOK
Company shares are trading in BSE.
Promoter holding: 48.32 % as on Dec qtr.
Company posted 25.08 Cr top line in Dec
Qtr.
Net profit is 1.41 Cr bottom-line in Dec
Qtr.
Operating Profits were improved from last
Qtr.
Debt to equity ratio: 0.45
Stock is trading at Rs 149
Company is mainly engaged in the
business manufacturing of Iodine and Bromine derivatives, which is having huge
demand in pharma, chemical and food and fertiliser sectors. These products are
falling in both consumption and chemical theme domain is having a huge growth
potential in the future.
By considering above, and performance of
the company over QOQ investors will get handsome returns in a days to come.
NOTE
: THE ABOVE IS NOT A RESEARCH REPORT NOR A RECOMMENDATION BUT INFORMATION
AS AVAILABLE ON PUBLIC DOMAIN.
Registration
status with SEBI: I am not registered with SEBI under the (Research Analyst)
regulations 2014 and as per clarifications provided by SEBI: “Any person who makes recommendation or offers an
opinion concerning securities or public offers only through public media is not
required to obtain registration as research analyst under RA Regulations”